If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

CEO Lars Fruergaard Jorgensen expressed concern, stating that only Novo Nordisk makes real semaglutide and does not supply it ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement ...

The Snook City Council has approved the creation of a tax reinvestment zone for C-LARS, LLC, a manufacturer of launch and recovery systems as a first step before later offering tax abatements.The ...

Researcher Tavs Jorgensen has created a method of extruding cob into brick shapes, in an effort to make the low-carbon biomaterial more accessible. Used to create bricks that can be stacked in ...